Relief Therapeutics and NeuroRx conclude target enrolment in RLF-100 trial

A Phase IIb/III trial with inhaled RLF-100 in patients with moderate and severe Covid-19 is likely to begin soon. Credit: Fusion Medical Animation on Unsplash.